Novartis Expands In Protein Degradation, Complements Radioligand Platform With Arvinas Deal

Deal Snapshot: The company told Scrip that part of why it licensed Arvinas’s ARV-766 and took over AR-V7 was to complement its radioligand therapy platform in prostate cancer.